BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28796995)

  • 1. Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score.
    Pollard ME; Hobbs AR; Kwon YS; Katsigeorgis M; Lavery HJ; Levinson A; Bernstein AN; Collingwood SA; Hall SJ; Jazayeri SB; Samadi DB
    Oncol Res Treat; 2017; 40(9):508-514. PubMed ID: 28796995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Bates AS; Mouraviev V; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Jun; 11(2):129-138. PubMed ID: 27435701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for short-term biochemical recurrence-free survival after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients.
    Kanehira M; Takata R; Ishii S; Ito A; Ikarashi D; Matsuura T; Kato Y; Obara W
    Int J Clin Oncol; 2019 Sep; 24(9):1099-1104. PubMed ID: 30972506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of D'Amico criteria for low-risk prostate cancer.
    Milonas D; Kinčius M; Skulčius G; Matjošaitis AJ; GudinavičienĖ I; Jievaltas M
    Scand J Urol; 2014 Aug; 48(4):344-9. PubMed ID: 24521187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
    Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
    Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
    Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
    Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long term biochemical recurrence free survival after radical prostatectomy for cancer: comparative analysis according to surgical approach and clinicopathological stage].
    Rizk J; Ouzzane A; Flamand V; Fantoni JC; Puech P; Leroy X; Villers A
    Prog Urol; 2015 Mar; 25(3):157-68. PubMed ID: 25614075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
    Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K
    Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.
    Izadmehr S; Leapman M; Hobbs AR; Katsigeorgis M; Nabizada-Pace F; Jazayeri SB; Samadi DB
    Int Urol Nephrol; 2016 Oct; 48(10):1639-45. PubMed ID: 27318820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
    Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High-risk prostate cancer surgical margins during robot-assisted radical prostatectomy].
    Duperron C; Moulin M; Koutlidis N; Mourey E; Cormier L
    Prog Urol; 2015 Jun; 25(7):390-5. PubMed ID: 25759079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of oncological and functional outcomes of pure versus robotic-assisted laparoscopic radical prostatectomy performed by a single surgeon.
    Park B; Kim W; Jeong BC; Jeon SS; Lee HM; Choi HY; Seo SI
    Scand J Urol; 2013 Feb; 47(1):10-8. PubMed ID: 22835035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic radical prostatectomy monotherapy, a more aggressive yet less invasive option, is oncologically effective in selected men with high-risk prostate cancer having only one D'Amico risk factor: experience from an Asian tertiary referral center.
    Tai HC; Lai MK; Huang CY; Wang SM; Huang KH; Chen CH; Chung SD; Chueh SC; Yu HJ; Pu YS
    J Endourol; 2014 Feb; 28(2):165-71. PubMed ID: 23987245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
    Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
    BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
    Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
    World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.